Ipecac’s status
This article was originally published in The Tan Sheet
Executive Summary
Recommendations by FDA's Nonprescription Drugs Advisory Committee meeting June 12 to discontinue Ipecac's OTC status "do not adequately represent the perspective of many practicing medical toxicologists," Richard Dart, MD/PhD, says in July 22 comments filed with the agency (1"The Tan Sheet" June 16, 2003, p. 3). Ipecac is useful in cases of iron and acetaminophen ingestion and for households in rural areas, the Rocky Mountain Poison Center Director argues. Therefore, Dart requests FDA wait until the tentative final monograph for OTC Poison Treatment Drug Products is "adopted before making its decision on the fate of syrup of Ipecac"...
You may also be interested in...
Ipecac OTC Status Withdrawal Advised By NDAC Majority
Ipecac syrup should not retain its OTC status as a treatment for accidental poisonings, a majority of the FDA Nonprescription Drugs Advisory Committee agreed at a June 12 meeting in Bethesda, Md
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.